share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Borgeson Blake

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Borgeson Blake

Recursion Pharmaceuticals | 4：持股变动声明-董事 Borgeson Blake
美股sec公告 ·  06/05 18:17
Moomoo AI 已提取核心信息
Recursion Pharmaceuticals, Inc. (RXRX) reported that Blake Borgeson, a key figure at the company, was granted 13,097 shares of Class A Common Stock on June 3, 2024. The transaction, which was completed on the same day, was a grant with a transaction price of $0.00 per share, indicating that the shares were likely awarded as part of a compensation package or incentive plan. Following this transaction, Borgeson's direct holdings in the company have increased to a total of 7,200,010 shares of Common Stock.
Recursion Pharmaceuticals, Inc. (RXRX) reported that Blake Borgeson, a key figure at the company, was granted 13,097 shares of Class A Common Stock on June 3, 2024. The transaction, which was completed on the same day, was a grant with a transaction price of $0.00 per share, indicating that the shares were likely awarded as part of a compensation package or incentive plan. Following this transaction, Borgeson's direct holdings in the company have increased to a total of 7,200,010 shares of Common Stock.
Recursion Pharmaceuticals, Inc.（RXRX）表示该公司的核心人物Blake Borgeson于2024年6月3日被授予了13,097股A类普通股。该交易于同一日完成，每股交易价格为0.00美元，表明这些股份很可能是作为报酬计划或激励计划的一部分授予的。在此交易后，Borgeson在该公司的直接持股增至总共7,200,010股普通股。
Recursion Pharmaceuticals, Inc.（RXRX）表示该公司的核心人物Blake Borgeson于2024年6月3日被授予了13,097股A类普通股。该交易于同一日完成，每股交易价格为0.00美元，表明这些股份很可能是作为报酬计划或激励计划的一部分授予的。在此交易后，Borgeson在该公司的直接持股增至总共7,200,010股普通股。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息